Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
The Mesothelioma Applied Research Foundation announced its latest research grant recipients, awarding a total of $300,000 at the International Symposium on Malignant Mesothelioma in Philadelphia
Many of our MesoTV episodes and other educational materials discuss the patient: their stories, their emotions, the science behind their diagnosis. This episode is solely
Vivace Therapeutics, a company that develops cancer treatments, announced on July 30, 2025, that the U.S. Food and Drug Administration (FDA) has granted its experimental